Silence Therapeutics priced an upsized public offering tied to its short interfering RNA pipeline after reporting a Phase 2 “best-case” outcome for divesiran in a rare leukemia. The financing expands expected gross proceeds to about $175 million, giving the company runway as it pushes multiple RNA assets toward later stages. In antibody capital raises, AbCellera launched an underwritten public offering targeting $200 million to fund menopause and hot-flash programs led by ABCL635 and ABCL365. The rounds underscore how clinical catalysts—especially Phase 2 data—are increasingly used to unlock capital-market liquidity for therapeutic platform companies.